NEW YORK (GenomeWeb) – Cancer Genetics today announced that it has entered into a research collaboration with the Moffitt Cancer Center in Tampa, Florida aimed at examining the influence of genetic variants on a patient's response to chemotherapy and other cancer-related treatments.

Cancer Genetics will integrate validated biomarkers from these studies into a comprehensive next-generation sequencing-based pharmacogenomics panel for clinical trials, which it plans to launch later this year, the firm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

Aug
09
Sponsored by
Agena Bioscience

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.